MA43347A - Compositions et méthodes permettant d'inhiber l'expression du gène de lpa - Google Patents

Compositions et méthodes permettant d'inhiber l'expression du gène de lpa

Info

Publication number
MA43347A
MA43347A MA43347A MA43347A MA43347A MA 43347 A MA43347 A MA 43347A MA 43347 A MA43347 A MA 43347A MA 43347 A MA43347 A MA 43347A MA 43347 A MA43347 A MA 43347A
Authority
MA
Morocco
Prior art keywords
agents
arni
lpa
compositions
methods
Prior art date
Application number
MA43347A
Other languages
English (en)
Other versions
MA43347B1 (fr
Inventor
Aaron Almeida
Lauren J Almeida
Steven Kanner
David L Lewis
Zhen Li
Tao Pei
David B Rozema
Vladimir S Trubetskoy
Darren H Wakefield
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Publication of MA43347A publication Critical patent/MA43347A/fr
Publication of MA43347B1 publication Critical patent/MA43347B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Des agents d'interférence d'arn (arni) et des conjugués d'agents d'arni pour inhiber l'expression du gène de la lpa (apo (a)) sont décrits. Des compositions pharmaceutiques comprenant un ou plusieurs agents arni lpa, éventuellement avec un ou plusieurs agents thérapeutiques supplémentaires, sont également décrites. La délivrance des agents arni lpa décrits aux cellules hépatiques in vivo permet d'inhiber l'expression du gène lpa et le traitement des maladies cardiovasculaires et cardiovasculaires.
MA43347A 2015-10-01 2017-04-06 Compositions et méthodes permettant d'inhiber l'expression du gène de lpa MA43347B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562235816P 2015-10-01 2015-10-01
US201662346304P 2016-06-06 2016-06-06
US201662383221P 2016-09-02 2016-09-02
PCT/US2016/054729 WO2017059223A2 (fr) 2015-10-01 2016-09-30 Compositions et méthodes permettant d'inhiber l'expression du gène de lpa

Publications (2)

Publication Number Publication Date
MA43347A true MA43347A (fr) 2018-08-08
MA43347B1 MA43347B1 (fr) 2021-11-30

Family

ID=58424351

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43347A MA43347B1 (fr) 2015-10-01 2017-04-06 Compositions et méthodes permettant d'inhiber l'expression du gène de lpa

Country Status (36)

Country Link
US (4) US9932586B2 (fr)
EP (2) EP3356529B1 (fr)
JP (5) JP6991966B2 (fr)
KR (1) KR102728481B1 (fr)
CN (1) CN108368506A (fr)
AU (3) AU2016331084B2 (fr)
CA (1) CA3000397A1 (fr)
CL (1) CL2018000803A1 (fr)
CO (1) CO2018003678A2 (fr)
CR (1) CR20180231A (fr)
CY (1) CY1125263T1 (fr)
DK (1) DK3356529T3 (fr)
EA (1) EA038478B1 (fr)
ES (1) ES2896298T3 (fr)
HR (1) HRP20211410T1 (fr)
HU (1) HUE055942T2 (fr)
IL (3) IL300438A (fr)
JO (2) JOP20210043A1 (fr)
LT (1) LT3356529T (fr)
MA (1) MA43347B1 (fr)
MX (2) MX2018003833A (fr)
MY (1) MY195796A (fr)
PE (1) PE20181139A1 (fr)
PH (1) PH12018500713A1 (fr)
PL (1) PL3356529T3 (fr)
PT (1) PT3356529T (fr)
RS (1) RS62523B1 (fr)
SG (1) SG10202008530TA (fr)
SI (1) SI3356529T1 (fr)
SM (1) SMT202100622T1 (fr)
TN (1) TN2018000094A1 (fr)
TW (3) TWI836693B (fr)
UA (1) UA121998C2 (fr)
UY (1) UY36926A (fr)
WO (1) WO2017059223A2 (fr)
ZA (1) ZA202106265B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718133B2 (en) 2003-10-09 2010-05-18 3M Innovative Properties Company Multilayer processing devices and methods
MX2018009854A (es) * 2016-03-07 2018-11-09 Arrowhead Pharmaceuticals Inc Ligandos dirigidos para compuestos terapeuticos.
CN116832169A (zh) * 2016-09-02 2023-10-03 箭头药业股份有限公司 靶向配体
RS63836B1 (sr) 2017-04-05 2023-01-31 Silence Therapeutics Gmbh Proizvodi i sastavi
KR20200024793A (ko) * 2017-07-06 2020-03-09 애로우헤드 파마슈티컬스 인코포레이티드 알파-ENaC의 발현을 억제하기 위한 RNAi 작용제 및 사용 방법
JOP20200054A1 (ar) * 2017-09-11 2020-03-10 Arrowhead Pharmaceuticals Inc عوامل RNAi وتركيبات لتثبيط تعبير صَميمُ البروتينِ الشَّحْمِيّ C-III (APOC3)
AU2018331383B2 (en) * 2017-09-14 2024-12-05 Arrowhead Pharmaceuticals, Inc. RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use
CN111655268B (zh) 2017-10-04 2024-03-26 艾维迪提生物科学公司 核酸-多肽组合物及其用途
WO2019079294A1 (fr) * 2017-10-17 2019-04-25 Arrowhead Pharmaceuticals, Inc. Agents à base d'arni et compositions destinées à inhiber l'expression du récepteur 1 de l'asialoglycoprotéine
IL274503B2 (en) * 2017-11-13 2024-10-01 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of lpa in a cell
EP3483270A1 (fr) * 2017-11-13 2019-05-15 Silence Therapeutics GmbH Produits et compositions
CA3109553A1 (fr) * 2018-09-19 2020-03-26 Arrowhead Pharmaceuticals, Inc. Agents d'arni d'inhibition de l'expression de 17beta-hsd de type 13- (hsd17b13), leurs compositions et methodes d'utilisation
JP7245328B2 (ja) * 2018-11-13 2023-03-23 サイレンス・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 細胞におけるｌｐａの発現を抑制するための核酸
US11578090B2 (en) * 2019-06-06 2023-02-14 Avidity Biosciences, Inc. Nucleic acid-polypeptide compositions and uses thereof
EP3983077A4 (fr) * 2019-06-17 2023-12-20 Alnylam Pharmaceuticals, Inc. Administration d'oligonucléotides au striatum
CN112442499B (zh) * 2019-08-30 2026-03-10 恩康药业科技（广州）有限公司 一种抑制MCM7的siRNA、组合物及其应用
US20230078200A1 (en) * 2019-12-09 2023-03-16 Amgen Inc. RNAi CONSTRUCTS AND METHODS FOR INHIBITING LPA EXPRESSION
AU2021244329A1 (en) * 2020-03-23 2022-09-29 Amgen Inc. Monoclonal antibodies to chemically-modified nucleic acids and uses thereof
JP7476422B2 (ja) 2020-08-05 2024-04-30 ディセルナ ファーマシューティカルズ インコーポレイテッド Ｌｐａ発現を阻害するための組成物及び方法
US20240035029A1 (en) * 2020-10-16 2024-02-01 Sanofi Rna compositions and methods for inhibiting lipoprotein(a)
MX2023005198A (es) * 2020-11-05 2023-05-16 Amgen Inc Metodos para tratar la enfermedad cardiovascular aterosclerotica con constructos de iarn dirigidos a lpa.
WO2022121959A1 (fr) * 2020-12-09 2022-06-16 纳肽得有限公司 Molécule d'arnsi et son application dans le traitement de maladies des artères coronaires
EP4237561A1 (fr) 2020-12-23 2023-09-06 Argonaute Rna Limited Traitement d'une maladie cardiovasculaire
JP2024523237A (ja) 2021-06-18 2024-06-28 ホンジーン バイオテック コーポレイション 官能化されたｎ－アセチルガラクトサミンヌクレオシド
EP4396193A4 (fr) 2021-08-30 2025-07-02 Hongene Biotech Corp Analogues de n-acétylgalactosamine fonctionnalisés
JP2024531728A (ja) 2021-09-14 2024-08-29 アルゴノート アールエヌエー リミテッド 心血管疾患の処置
AU2022348141A1 (en) * 2021-09-18 2024-04-04 Chengdu Xinzhenghe Pharmaceutical Technology Co. Ltd Lpa inhibitor and use thereof
MX2024005862A (es) 2021-11-16 2024-07-10 Shanghai Argo Biopharmaceutical Co Ltd Composiciones y metodos para inhibir la expresion de la proteina angiotensinogeno (agt).
EP4448540A1 (fr) 2021-12-15 2024-10-23 Hongene Biotech Corporation Analogues de n-acétylgalactosamine fonctionnalisés
EP4450624A4 (fr) * 2021-12-16 2025-03-26 Tuojie Biotech (Shanghai) Co., Ltd. Arnsi ciblant le lpa et conjugué
CN114703184B (zh) * 2022-03-11 2024-06-18 厦门甘宝利生物医药有限公司 Lpa抑制剂及其用途
CN119698469A (zh) * 2022-08-11 2025-03-25 益杰立科(上海)生物科技有限公司 一种表观编辑靶点的方法及用途
CN115851723B (zh) * 2022-10-24 2023-10-03 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用
WO2024118503A1 (fr) 2022-11-28 2024-06-06 Hongene Biotech Corporation Analogues de n-acétylgalactosamine fonctionnalisés
JP2026502533A (ja) * 2023-01-13 2026-01-23 イーライ リリー アンド カンパニー 治療用オリゴヌクレオチド含有医薬組成物及びそれを用いる投与レジメン
WO2024210530A1 (fr) * 2023-04-03 2024-10-10 Olix Pharmaceuticals, Inc. Agents arni ciblant le gène lpa et leur utilisation
CN121127587A (zh) * 2023-04-24 2025-12-12 上海京新生物医药有限公司 用于抑制LPA表达的RNAi剂及其应用
EP4714939A1 (fr) 2023-05-19 2026-03-25 Shenzhen Salubris Pharmaceuticals Co., Ltd. Composé sulfonamide, son procédé de préparation et son utilisation pharmaceutique
CN119343449A (zh) * 2023-05-24 2025-01-21 云合智药（苏州）生物科技有限公司 用于抑制angptl3表达的rnai剂及其应用
AU2024280186A1 (en) 2023-05-31 2025-12-04 Tuojie Biotech (Shanghai) Co., Ltd. Dsrna targeting lpa and use thereof
KR20260034076A (ko) * 2023-05-31 2026-03-10 애로우헤드 파마슈티컬스 인코포레이티드 다량체성 RNAi 작용제 접합체를 위한 간 전달 플랫폼 및 그의 사용 방법
DE102023115075A1 (de) * 2023-06-07 2024-12-12 B.Braun Avitum Ag Schlauchrollenpumpe
WO2025064821A2 (fr) 2023-09-21 2025-03-27 Ionis Pharmaceuticals, Inc. Composés et procédés d'inhibition de lpa
WO2025082058A1 (fr) * 2023-10-16 2025-04-24 润佳(上海)医药技术有限公司 Arn double brin inhibant l'expression du gène lpa et son utilisation
CN120344664A (zh) * 2023-10-27 2025-07-18 北京安龙生物医药有限公司 靶向脂蛋白a的寡核苷酸及其用途
TW202540420A (zh) * 2023-11-15 2025-10-16 大陸商北京加科瑞康醫藥科技有限公司 用於抑制LPA的基因表現的siRNA，含其的組合物及其用途
CN120020252A (zh) * 2023-11-17 2025-05-20 纳肽得(青岛)生物医药有限公司 抑制LPA表达的siRNA及其用途
CN120098993A (zh) * 2023-12-05 2025-06-06 广东东阳光药业股份有限公司 一种新型的双链siRNA、其缀合物及其用途
CN120485189B (zh) * 2025-07-16 2025-10-17 北京悦康科创医药科技股份有限公司 靶向调控LPA基因表达的siRNA及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
WO2000053722A2 (fr) 1999-03-10 2000-09-14 Phogen Limited Administration de substances a des cellules
KR100909681B1 (ko) * 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Ｒｎａ 간섭을 매개하는 작은 ｒｎａ 분자
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en) 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
EP1613348B1 (fr) 2003-03-12 2010-06-23 The Arizona Board of Regents on Behalf of the University of Arizona Procedes de modulation de l'angiogenese avec des compositions d'apeline
US8084599B2 (en) 2004-03-15 2011-12-27 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
CN101500548A (zh) * 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
CN102325534B (zh) 2008-12-18 2016-02-17 戴瑟纳制药公司 延长的dicer酶底物和特异性抑制基因表达的方法
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
SG183374A1 (en) 2010-02-24 2012-09-27 Arrowhead Res Corp Compositions for targeted delivery of sirna
US8865675B2 (en) * 2010-05-12 2014-10-21 Protiva Biotherapeutics, Inc. Compositions and methods for silencing apolipoprotein B
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
CA2816155C (fr) * 2010-12-17 2020-10-27 Arrowhead Research Corporation Fraction de ciblage complexe de galactose-modulateur pharmacocinetique pour arnsi
SG189942A1 (en) 2010-12-29 2013-06-28 Arrowhead Res Corp In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
HK1199736A1 (en) 2011-08-26 2015-07-17 箭头研究公司 Poly(vinyl ester) polymers for in vivo nucleic acid delivery
WO2013075035A1 (fr) * 2011-11-18 2013-05-23 Alnylam Pharmaceuticals Agents arni, compositions et procédés d'utilisation de ceux-ci pour traiter des maladies associées à la transthyrétine (ttr)
WO2013158141A1 (fr) 2012-04-18 2013-10-24 Arrowhead Research Corporation Polymères de poly(acrylate) pour une administration d'acide nucléique in vivo
WO2013177468A2 (fr) * 2012-05-24 2013-11-28 Isis Pharmaceuticals, Inc. Procédés et compositions de modulation de l'expression de l'apolipoprotéine(a)
WO2014134483A2 (fr) * 2013-02-28 2014-09-04 Immunogen, Inc. Conjugués comprenant des agents de liaison cellulaire (cba) et des agents cytotoxiques
PE20152002A1 (es) * 2013-05-01 2016-01-21 Isis Pharmaceuticals Inc Composiciones y metodos para modular la expresion de ttr y vhb
US20160272970A1 (en) 2015-03-17 2016-09-22 Arrowhead Madison Inc. RNA Interference Agents
WO2016196239A1 (fr) 2015-05-29 2016-12-08 Arrowhead Pharmaceuticals, Inc. Compositions et méthodes permettant d'inhiber l'expression du gène de hif2alpha
PL3329002T3 (pl) * 2015-07-31 2021-04-19 Alnylam Pharmaceuticals, Inc. Kompozycje irna transtyretyny (ttr) i sposoby ich zastosowania do leczenia lub zapobiegania chorobom związanym z ttr
MX2018009854A (es) 2016-03-07 2018-11-09 Arrowhead Pharmaceuticals Inc Ligandos dirigidos para compuestos terapeuticos.

Also Published As

Publication number Publication date
AU2022283623A1 (en) 2023-02-02
JP6991966B2 (ja) 2022-02-03
WO2017059223A9 (fr) 2017-08-17
JP2024009262A (ja) 2024-01-19
PH12018500713A1 (en) 2018-10-15
US20170096665A1 (en) 2017-04-06
AU2025242219A1 (en) 2025-10-23
SMT202100622T1 (it) 2022-01-10
WO2017059223A2 (fr) 2017-04-06
NZ741086A (en) 2023-11-24
EA038478B1 (ru) 2021-09-03
UY36926A (es) 2017-04-28
TWI836693B (zh) 2024-03-21
SG10202008530TA (en) 2020-10-29
MX2018003833A (es) 2018-06-18
TW202449154A (zh) 2024-12-16
JOP20210043A1 (ar) 2017-06-16
PL3356529T3 (pl) 2021-12-20
EP4029941A1 (fr) 2022-07-20
CA3000397A1 (fr) 2017-04-06
JP2022113835A (ja) 2022-08-04
US10662427B2 (en) 2020-05-26
ES2896298T3 (es) 2022-02-24
DK3356529T3 (da) 2021-11-08
JOP20160211B1 (ar) 2021-08-17
TW202332769A (zh) 2023-08-16
WO2017059223A3 (fr) 2017-05-11
JP2026040461A (ja) 2026-03-09
JP7442574B2 (ja) 2024-03-04
CR20180231A (es) 2018-05-31
CY1125263T1 (el) 2023-03-24
JP7116212B2 (ja) 2022-08-09
IL300438A (en) 2023-04-01
US9932586B2 (en) 2018-04-03
NZ780687A (en) 2025-06-27
US20250115907A1 (en) 2025-04-10
KR102728481B1 (ko) 2024-11-12
TWI784934B (zh) 2022-12-01
TN2018000094A1 (en) 2019-07-08
BR112018006489A2 (pt) 2018-10-09
SI3356529T1 (sl) 2022-01-31
IL290566A (en) 2022-04-01
MA43347B1 (fr) 2021-11-30
TWI880645B (zh) 2025-04-11
CO2018003678A2 (es) 2018-11-30
HRP20211410T1 (hr) 2021-12-24
MX2022013010A (es) 2022-11-09
LT3356529T (lt) 2021-12-27
TW201726918A (zh) 2017-08-01
KR20180052703A (ko) 2018-05-18
JP2021087459A (ja) 2021-06-10
JP2018529732A (ja) 2018-10-11
HUE055942T2 (hu) 2022-01-28
IL258333A (en) 2018-05-31
CN108368506A (zh) 2018-08-03
RS62523B1 (sr) 2021-11-30
EA201890864A1 (ru) 2018-09-28
UA121998C2 (uk) 2020-08-25
AU2016331084A1 (en) 2018-04-19
ZA202106265B (en) 2023-08-30
US20200263179A1 (en) 2020-08-20
HK1259063A1 (en) 2019-11-22
KR20240162596A (ko) 2024-11-15
MY195796A (en) 2023-02-21
EP3356529A4 (fr) 2019-09-04
IL290566B2 (en) 2023-07-01
EP3356529B1 (fr) 2021-08-25
EP3356529A2 (fr) 2018-08-08
PE20181139A1 (es) 2018-07-17
IL290566B1 (en) 2023-03-01
PT3356529T (pt) 2021-11-04
IL258333B (en) 2022-03-01
US20180195070A1 (en) 2018-07-12
AU2022283623B2 (en) 2025-07-10
CL2018000803A1 (es) 2018-08-31
AU2016331084B2 (en) 2022-09-08

Similar Documents

Publication Publication Date Title
MA43347A (fr) Compositions et méthodes permettant d'inhiber l'expression du gène de lpa
PH12020500332A1 (en) Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
MY200087A (en) Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
EP4272731A3 (fr) Compositions pour l'administration d'agents thérapeutiques et leurs méthodes d'utilisation et leurs procédés de préparation
MA40791A (fr) Ciblage lysosomal d'enzymes et utilisations associées
WO2018140920A8 (fr) Compositions et méthodes d'inhibition de l'expression génique du facteur xii
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
HK1203356A1 (en) Pharmaceutical combinations comprising a thionucleotide analog
TN2015000174A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
MX2021013582A (es) Composiciones que comprenden agentes biologicamente activos y sales biliares.
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
EA201692318A1 (ru) Композиции и способы для ингибирования экспрессии гена альфа-1-антитрипсина
JOP20190263A1 (ar) عوامل RNAi لتثبيط التعبير عن Alpha- EnaC وطرق استخدامها
EA201792103A1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
MX2016015211A (es) Formulaciones topicas y usos de las mismas.
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
WO2016030899A8 (fr) Méthodes de traitement de la sclérose latérale amyotrophique
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
TW202609059A (zh) 用於抑制類血管生成素蛋白-3 (ANGPTL3)表現的RNAi藥劑及組合物及使用方法
CR20200117A (es) Agentes de iarn y composiciones para inhibir la expresión de la angiopoyetina tipo 3 (angptl3) y métodos de uso
EA202090234A1 (ru) СРЕДСТВА РНКи ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ АЛЬФА-ENaC И СПОСОБЫ ПРИМЕНЕНИЯ
Ballis NAPSA: NAPSA charity cup campaign reaches new heights
UA110910C2 (uk) Карбоксамідні похідні піразолу як інгібітори тирозинкінази брутона, фармацевтична композиція на їх основі та спосіб лікування захворювань (варіанти)